"Die Inneren Medizin II umfasst die Hämatologie, Onkologie, klinische Immunologie und Rheumatologie. Unser Fokus liegt auf der Behandlung von Leukämien, Lymphomen und der Durchführung von Stammzelltransplantationen und Zelltherapien. Durch die enge Verzahnung unserer Patientenversorgung mit klinischen Studien und der experimentellen Forschung, entwickeln wir Therapieansätze für bislang nicht behandelbare Erkrankungen. Diese basieren auf neuen Methoden entwickelt aus den aktuellsten wissenschaftlichen Erkenntnissen und den höchsten klinischen Standards."

During the past decade, Klinikum der Eberhard-Karls-Universität/Abt. für innere Med. II/Hämatologie/Onkologie-Germany conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Klinikum der Eberhard-Karls-Universität/Abt. für innere Med. II/Hämatologie/Onkologie-Germany" #1 collaborator was "Legend Biotech" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Klinikum der Eberhard-Karls-Universität/Abt. für innere Med. II/Hämatologie/Onkologie-Germany" are "Multiple Myeloma" (5 trials) and "Relapsed/Refractory Multiple Myeloma" (1 trials). Many other conditions were trialed in "Klinikum der Eberhard-Karls-Universität/Abt. für innere Med. II/Hämatologie/Onkologie-Germany" in a lesser frequency.

Most popular intervention types in "Klinikum der Eberhard-Karls-Universität/Abt. für innere Med. II/Hämatologie/Onkologie-Germany" are "Drug" (4 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bortezomib" (3 trials), "Dexamethasone" (3 trials), "Daratumumab" (2 trials), "JNJ-68284528" (2 trials) and "Lenalidomide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Klinikum der Eberhard-Karls-Universität/Abt. für innere Med. II/Hämatologie/Onkologie-Germany" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Klinikum der Eberhard-Karls-Universität/Abt. für innere Med. II/Hämatologie/Onkologie-Germany". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Klinikum der Eberhard-Karls-Universität/Abt. für innere Med. II/Hämatologie/Onkologie-Germany, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Klinikum der Eberhard-Karls-Universität/Abt. für innere Med. II/Hämatologie/Onkologie-Germany, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".